Clinical trials: Chronic Obstructive Pulmonary Disease, Unspecified
- Condition Chronic Obstructive Pulmonary Disease, Unspecified
- Funder type Industry (pharma, biotech, devices)
Obesity Hypoventilation Syndrome, Obstructive Sleep Apnea
Simplus and Eson Non-Invasive Ventilation (NIV) Evaluation - Germany
This investigation is designed to evaluate the performance, comfort and ease of use of the Simplus and Eson masks amongst NIV patients who are currently on Bi-level therapy
- Conditions
- Obesity Hypoventilation Syndrome, Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease, Neuromuscular Disease
- Trial name
- NCT02726048
- Testing
- Simplus/Eson
- Where
- Germany
- Volunteers
- 4 people
- Sponsor
- Fisher and Paykel Healthcare
Pulmonary Disease, Chronic Obstructive
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of the study is to identify demographic and non-spirometric clinical features predictive of the asthma-COPD overlap population.
- Trial name
- NCT02302417
- Testing
- Spirometry, ACOS clinical questionnaire
- Where
- 42 sites in United States, Argentina and 3 more
- Volunteers
- 1,215 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Postmarketing Surveillance Study of Atrovent® Inhalation Solution in Chronic Obstructive Pulmonary Disease
To obtain further information on the tolerability and efficacy of Atrovent® 500µg/2ml inhalation solution in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice
- Trial name
- NCT02238197
- Testing
- Atrovent® Inhalation Solution
- Volunteers
- 477 people
- Sponsor
- Boehringer Ingelheim
Asthma-COPD Overlap Syndrome
A Non-interventional Study to Investigate the Current Situation of Asthma-COPD Overlap Syndrome in Patients Over Age 40 With Persistent Airflow Limitation in China
To investigate the distributions of the patients with ACOS, asthma and COPD over age 40 with chronic airflow limitation in China.
- Trial name
- NCT02600221
- Where
- 13 sites in China
- Volunteers
- 2,016 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Effect of Aclidinium/Formoterol on Lung Hyperinflation, Exercise Capacity and Physical Activity in Moderate to Severe COPD Patients
The present study is planned to evaluate the effect of the aclidinium bromide/formoterol fumarate 400/12 μg FDC BID on the hyperinflation, exercise endurance and physical activity in patients with moderate to severe COPD.
- Trial name
- ACTIVATE (NCT02424344)
- Testing
- Aclidinium/Formoterol
- Where
- 26 sites in Canada, Germany and 2 more
- Volunteers
- 267 people
- Sponsor
- AstraZeneca
Chronic Obstructive Lung Disease (COLD)
Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)
To evaluate the safety and efficacy of the HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension compared with the placebo in the treatment of Chinese patients with COPD.
- Trial name
- NCT07140328
- Testing
- HSK39004 Dry Powder Inhaler -0.75mg BID, HSK39004 Dry Powder Inhaler -1.5mg BID, HSK39004 Inhalation Suspension -3mg BID
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Pulmonary Disease, Chronic Obstructive
Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II
The primary objective of this study is to assess the long-term efficacy and safety of once daily treatment of BI 1744 CL inhalation solution (5 and 10 mcg) delivered via the Respimat® inhaler, in patients with COPD.
- Trial name
- NCT00796653
- Testing
- Olodaterol (BI 1744), Formoterol
- Where
- 98 sites in Argentina, Brazil and 18 more
- Volunteers
- 937 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Comparing the Efficacy of Tiotropium + Olodaterol Fixed Dose Combination (FDC) Over Tiotropium in Improvement of Lung Hyperinflation, Exercise Capacity and Physical Activity in Japanese COPD Patients
This is a multi-centre, randomised, double-blinded, active-controlled, 2-way cross over trial to assess the effects of once daily administration of orally inhaled tiotropium + olodaterol FDC or tiotropium (both delivered by the…
- Trial name
- NCT02629965
- Testing
- tiotropium, olodaterol
- Where
- 43 sites in Japan
- Volunteers
- 184 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
High Intensity Non-Invasive Positive Pressure Ventilation (HINPPV)
The purpose of this pilot study is to evaluate the effect of high intensity non-invasive positive pressure ventilation (HINPPV) for stable, hypercapnic COPD patients.
- Trial name
- HINPPV (NCT01214200)
- Testing
- Bilevel positive airway pressure (BiPAP)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Philips Respironics
Pulmonary Disease, Chronic Obstructive
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease
The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of FF/VI 100/25mcg once daily compared with Fluticasone Propionate/Salmeterol 250/50mcg twice daily over a 12-week treatment period in subjects with…
- Trial name
- NCT01323634
- Testing
- Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg, Fluticasone Propionate 250mcg/ salmeterol 50mcg
- Where
- 50 sites in United States, Czechia and 4 more
- Volunteers
- 519 people
- Sponsor
- GlaxoSmithKline
COPD
Effects of Ergometer Training With Telemonitoring in Patients With Chronic Obstructive Pulmonary Disease (COPD) After Exacerbation
Home ergometer training combined with online monitoring and regular telephone support could prove to be a cost-effective method to improve physical performance and quality of life in COPD patients.
- Trial name
- COPD (NCT01987544)
- Testing
- Ergometer Training, Motivation
- Where
- Germany
- Volunteers
- 53 people
- Sponsor
- Institut für Pneumologie Hagen Ambrock eV
Chronic Obstructive Pulmonary Disease
NVA237 Versus Placebo 12-week Efficacy Study
The study serves to determine whether the treatment of patients with stable, symptomatic Chronic Obstructive Pulmonary Disease (COPD) with the investigational drug NVA237 is efficient and safe.
- Trial name
- NCT01709864
- Testing
- NVA237
- Where
- 54 sites in United States
- Volunteers
- 440 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Emphysema
Israeli 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation
The purpose of this study is to evaluate the safety and efficacy of the Aeris BLVR System in patients with advanced emphysema.
- Trial name
- NCT00205907
- Testing
- BLVR Hydrogel
- Where
- Israel
- Volunteers
- 4 people
- Sponsor
- Aeris Therapeutics
Chronic Obstructive Pulmonary Disease COPD
Long-term Real-world Study of Dupilumab in COPD : Patient Characteristics, Safety and Patient-reported Outcomes
The OBS19236 is a retrospective and prospective, non-interventional observational study in COPD patients treated with dupilumab as part of routine clinical care.
- Trial name
- AURORA (NCT07380711)
- Where
- 28 sites in France
- Volunteers
- 500 people
- Sponsor
- Sanofi
COPD (Chronic Obstructive Pulmonary Disease)
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial of JKN2403 in COPD
The goal of this clinical trial is to learn if drug JKN2403 works to treat moderate-to-severe COPD in adults. It will also learn about the safety and pharmacokinetic characteristics of drug JKN2403.
- Trial name
- COPD (NCT07351734)
- Testing
- JKN2403 Tablets
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Joincare Pharmaceutical Group Industry Co., Ltd
Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation
Effect of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease
The purpose of this trial is to investigate if roflumilast can reduce the neutrophilic inflammation at acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- TREAT (NCT01473758)
- Testing
- Roflumilast
- Where
- 2 sites in United Kingdom
- Volunteers
- 81 people
- Sponsor
- AstraZeneca
COPD
Continuous Monitoring of Patients With Chronic Obstructive Pulmonary Disease
An open, single group, single center Study to confirm CTC-Actiwise™ as a means to record and monitor the progression of a patient's COPD. Chronic Obstructive Pulmonary Disease (COPD) affects growing patient groups.
- Trial name
- CTC-Actiwise (NCT01741935)
- Where
- Sweden
- Volunteers
- 25 people
- Sponsor
- CareTelCom AB
Pulmonary Disease, Chronic Obstructive
A Study of UK-369,003 on the Safety and Efficacy in Patients With COPD
A randomised, controlled study investigating the effect of UK-369,003 on exercise tolerance in patients with COPD
- Trial name
- NCT00163098
- Testing
- UK-369,003
- Where
- 28 sites in Argentina, Australia and 3 more
- Volunteers
- 136 people
- Sponsor
- Pfizer
Pulmonary Disease, Chronic Obstructive
Clinical Evaluation Of GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)
This study compares the effect of two medicines on COPD (Chronic Obstructive Pulmonary Disease). This study will last up to 18 weeks, and subjects will visit the clinic 5 times.
- Trial name
- NCT00269126
- Testing
- fluticasone propionate/salmeterol combination DISKUS, salmeterol xinafoate
- Where
- 2 sites in Japan
- Volunteers
- 150 people
- Sponsor
- GlaxoSmithKline
COPD, Chronic Obstructive Pulmonary Disease
A Study to Assess the Effects of PT001 and PT005 MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPD
To assess the effect of treatment with Glycopyronnium (GP) MDI administered twice daily (BID) and Formoterol Fumarate (FF) MDI administered BID on specific image-based airway volumes and resistance in subjects with moderate to…
- Trial name
- NCT02937584
- Testing
- GP MDI (PT001) 14.4 μg, FF MDI (PT005) 9.6 μg
- Where
- 2 sites in Belgium
- Volunteers
- 23 people
- Sponsor
- Pearl Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.